Highest-materiality recent filing
Prothena Q1 net income $32.7M on $50M milestone; raises cash guidance
Net income of $32.7M ($0.60 diluted EPS) vs net loss of $60.2M ($1.12 loss) in Q1 2025.
Prothena authorizes up to $100M share repurchase plan through Dec 31, 2026
Board authorized repurchase of up to $100M of ordinary shares; plan expires Dec 31, 2026.
Prothena posts Q4 2025 net loss $21.6M; full-year loss $244.1M; 2026 cash burn guide $50-55M
Net loss $21.6M ($0.40 EPS) in Q4 vs $58.0M loss ($1.08 EPS) in Q4 2024; full-year loss $244.1M ($4.53 EPS).
Prothena Q3 net loss $36.5M, nine-month loss $222.5M on charges; pipeline advances
Net loss for Q3 2025 was $36.5M ($0.68/sh) vs $59.0M ($1.10/sh) in Q3 2024; nine-month loss $222.5M ($4.13/sh) vs $64.4M ($1.20/sh).
Prothena PRX012 shows amyloid reduction but higher ARIA-E rates; seeks partnership
Phase 1 ASCENT: PRX012 400 mg achieved mean amyloid PET reduction to 27.47 CL at month 12.
Prothena partner Novo Nordisk to advance coramitug to Phase 3 for ATTR-CM
Novo Nordisk plans Phase 3 program for coramitug in ATTR-CM, start expected in 2025.
Prothena Q2 net loss $125.8M; prasinezumab to enter Phase 3 by end 2025
Net loss $125.8M vs income $66.9M last year; includes $32.6M restructuring charge and $44.9M non-cash tax allowance.
Prothena cuts 63% of workforce, expects $16-20M severance costs; two C-suite execs to leave Aug 1
Workforce reduction of ~63% to cut operating costs; substantially complete by Q4 2025.
Roche to advance prasinezumab to Phase III for Parkinson’s; Phase IIb data missed primary endpoint
Partner Roche advancing prasinezumab into Phase III for early-stage Parkinson’s disease.
Phase 3 AFFIRM-AL did not meet primary endpoint of all-cause mortality (HR=0.915, p=0.7680); secondary endpoints also missed.
Prothena Q1 net loss $60.2M, cash $418.8M; AFFIRM-AL data due Q2 2025
Net loss $60.2M ($1.12/share) vs $72.2M ($1.34/share) year ago; revenue $2.8M (from BMS collaboration).
Prothena reports FY2024 net loss $122.3M; cash $472.2M; AFFIRM-AL topline expected Q2 2025
Net loss per share Q4 $1.08, FY2024 $2.27; total revenue FY2024 $135.2M (up from $91.4M prior year).
Net loss of $59.0M ($1.10 per share) vs net income of $21.9M ($0.38 diluted) in Q3 2023; revenue fell to $1.0M from $84.9M.
Prothena CMO Hideki Garren departs; Chad Swanson appointed Chief Development Officer
Hideki Garren, M.D., Ph.D., resigns as Chief Medical Officer effective Sept 27, 2024, to lead global product development at a large pharma.
Prothena Q2 net income $66.9M; BMS licenses PRX019 for $80M; year-end cash guidance raised to $468M
Q2 net income $66.9M (diluted EPS $1.22) vs net loss $54.6M in Q2 2023; revenue $132M vs $4M.
Prothena licenses PRX019 to BMS for $80M upfront; milestones up to $617.5M
Upfront payment of $80 million from BMS; eligible for additional development and regulatory milestones up to $242.5M.
Prothena Q4 2023 net loss $67.5M; cash $621M; guides 2024 cash burn ~$208-225M
Net loss Q4 $67.5M ($1.26 loss per share) vs net income $6.3M Q4 2022; full year loss $147.0M.
Prothena reports $621M cash at year-end 2023; pipeline updates on PRX012, PRX123, birtamimab
Cash, cash equivalents, and restricted cash ~$621M as of Dec 31, 2023; sufficient capital beyond ongoing trials.
Prothena reports Q3 net income of $21.9M; revenue surges to $84.9M on BMS license
Net income of $21.9M ($0.38 diluted EPS) vs net loss of $45.8M in Q3 2022; first nine months net loss of $79.6M.
Prothena Q2 net loss $54.6M, revises FY cash guidance up to ~$600M
Net loss $54.6M ($1.03/share) vs $41.2M loss in Q2 2022; revenue $4.0M (up from $1.3M).
Prothena expands BMS tau collaboration to global license; $55M fee, milestones up to $562.5M
BMS exercises option to convert US-only tau license to global; Prothena receives $55M exercise fee.
Prothena Q1 net loss widens to $46.9M; pipeline progress with PRX012, PRX005 data
Net loss of $46.9M ($0.89 per share) vs $36.3M ($0.78) in Q1 2022; revenue $2.2M from BMS collaboration.
Prothena reports Q4 net income $6.3M, full year net loss $116.9M; provides 2023 guidance
Q4 2022 revenue $49.9M (incl. $40M Novo Nordisk milestone); full year revenue $53.9M vs $200.6M in 2021.
Prothena launches $172.4M public offering of 3.25M ordinary shares at $53.11/share
Underwriters agreed to buy 3,250,000 ordinary shares at $53.11 per share; 30-day option for up to 487,500 additional shares.
Prothena earns $40M milestone from Novo Nordisk for ATTR cardiomyopathy drug advance
$40 million milestone payment from Novo Nordisk triggered by continued Phase 2 study of NNC6019 for ATTR cardiomyopathy.
Net loss $45.8M ($0.97 per share) vs net income $109.2M ($2.13 diluted EPS) in Q3 2021.
Prothena Q2 2022 net loss $41.2M vs net income $27.6M a year ago; cash $510.1M
Net loss of $41.2M ($0.88 loss per share) vs net income of $27.6M ($0.58 diluted EPS) in Q2 2021.
Prothena's PRX012 granted FDA Fast Track designation for Alzheimer's treatment
FDA Fast Track designation for PRX012, a next-generation anti-amyloid beta antibody for Alzheimer's.
FDA clears IND for Prothena's PRX012 subcutaneous anti-Aβ antibody; Phase 1 SAD study initiated
FDA cleared IND for PRX012, a potential best-in-class anti-amyloid beta antibody for Alzheimer's disease.
Prothena reports FY2021 net income of $67M; cash $580M; pipeline advances with SPA and partnerships
FY2021 revenue $200.6M (vs $0.9M in 2020); net income $67.0M vs net loss $111.1M in 2020.
Prothena enters $250M at-the-market equity distribution agreement
Agreement with Piper Sandler, Stifel, Cantor Fitzgerald, RBC Capital Markets, and JMP Securities.
Prothena reports Q3 net income of $109.2M vs loss; revenue $139.2M on partner payments
Q3 net income $109.2M ($2.13 diluted EPS) vs net loss $30.6M a year ago; 9-month net income $100.2M.
On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.
On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.
On September 23, 2024, Hideki Garren, M.D., Ph.D., Chief Medical Officer of Prothena Corporation plc (the “Company”) notified the Company that he is resigning from the Company effective September 27, 2024.
On February 21, 2024, the Board of Directors (the “Board”) of Prothena Corporation plc (the “Company”) increased the size of the Board and appointed Daniel G. Welch to serve as a director of the Company, effective immediately.
On May 16, 2023, the Board of Directors (the “Board”) of Prothena Corporation plc (the “Company”) increased the size of the Board and appointed William H. Dunn, Jr., M.D. to serve as a director of the Company, effective immediately.
On April 25, 2023, Dr. Sanjiv K. Patel notified Prothena Corporation plc (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”) and as a member of the Compensation Committee of the Board, effective as of July 1, 2023.
appointed Tran B. Nguyen to the additional and newly created role of the Company’s Chief Strategy Officer
Brandon S. Smith to replace Mr. Nguyen as the Company’s Chief Operating Officer
Max materiality 0.90 · Median 0.65 · Most common event earnings